



SANGAM HEALTHCARE PRODUCTS LIMITED Safti

(ISO 9001 Certified Company)

CIN L24230TG1993PLCO16731

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001.

Date: 13.11.2020

Dear Sir/Madam,

Sub: Outcome of board meeting under regulation 30 read with 33 (3) (c) of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Ref: Sangam Health Care Products Limited (Scrip code: 531625)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of Sangam Health Care Products Limited held on Friday, the 13th day of November, 2020 at 04:00 P.M. at the registered office of the company were duly considered and approved by the Board:

1. Un-audited Financial Results of the company as per IndAS for the quarter ended September 30, 2020 and
2. Limited review report of auditors thereon.

The meeting of the Board of Directors commenced at 04.00 P.M (IST) and concluded at 5.00 P.M (IST)

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Sangam Health Care Products Limited

A. Bala Gopal

A. Bala Gopal
Managing Director
DIN: (01712903)



Encl: as above

SANGAM HEALTHCARE PRODUCTS LIMITED							
Statement of Un-Audited Results for the Quarter Ended and Six Months Ended 30.09.2020						(Rs. in Lakhs)	
S.No.	Particulars	For the Quarter ended			Six Months Ended		Year Ended
		30.09.2020 (unaudited)	30.06.2020 (unaudited)	30.09.2019 (unaudited)	30.09.2020 (unaudited)	30.09.2019 (unaudited)	31.03.2020 (audited)
I.	Revenue from Operations	315.45	306.93	666.87	622.38	1,175.63	2,180.55
II.	Other Income	-	-	-	-	315.31	1.78
III.	Total Income (I+II)	315.45	306.93	666.87	622.38	1,490.94	2,182.33
IV.	Expenses						
	(a) Cost of Materials consumed	97.40	135.83	279.50	233.23	538.56	1,024.09
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	89.41	70.26	73.70	159.67	65.97	(39.29)
	(d) Employee benefits expense	60.96	46.02	122.85	106.98	252.21	552.44
	(e) Finance Cost	0.07	0.05	-	0.12	-	29.45
	(f) Depreciation and amortisation expense	31.38	31.39	34.11	62.77	71.68	125.54
	(g) Capital Expenditure Written Off	-	-	-	-	-	-
	(h) Net loss on de-recognition of financial assets at amortized cost	-	-	-	-	-	-
	(i) Net loss on reclassification of financial assets	-	-	-	-	-	-
	(j) Other expenses	64.04	69.53	162.51	133.57	289.07	440.05
	Total Expenses	343.26	353.08	672.67	696.34	1,217.49	2,132.28
V.	Profit / (Loss) before and exceptional items and Tax (III-IV)	-27.81	-46.15	-5.80	-73.96	273.45	50.05
VI.	Exceptional Items	-	-	-	-	-	(291.54)
VII.	Profit / (Loss) from before tax (V-VI)	-27.81	-46.15	-5.80	-73.96	273.45	341.59
VIII.	Tax expense						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	(63.94)
IX.	Net Profit / (Loss) for the year from continuing operations (VII-VIII)	-27.81	-46.15	-5.80	-73.96	273.45	405.53
	Discontinued Operations						
X.	Profit/(Loss) from discontinued operations	-	-	-	-	-	-
XI.	Tax expenses of discontinued operations	-	-	-	-	-	-
XII.	Net Profit / (Loss) for the year from Discontinuing operations (X-XI)	-	-	-	-	-	-
XIII.	Profit/(Loss) for the year (IX+XII)	-27.81	-46.15	-5.80	-73.96	273.45	405.53
XIV.	Other Comprehensive Income(OCI)						
	Items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XV.	Total Comprehensive Income	-27.81	-46.15	-5.80	-73.96	273.45	405.53
XVI.	Paid-up equity share capital (Face Value of Rs. 10/- per share)	1,486.07	1,486.07	1,486.07	1,486.07	1,486.07	1,486.07
XVII.	Earnings Per Equity Share of face value of Rs.10/- each]						
	a) Basic & Diluted (In Rs.)	(0.19)	(0.31)	(0.04)	(0.50)	1.84	2.73

NOTES:

- The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 13.11.2020
- These results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.
- The Company is engaged in manufacturing and sale of medical products hence there are no separate reportable segments as per Ind AS -108 "Operating Segments" is prepared

For SANGAM HEALTHCARE PRODUCTS LIMITED

A. Balagopal
A. Balagopal
Chairman and Managing Director
DIN:01712903



Place : Hyderabad
Date : 13/11/2020

SANGAM HEALTHCARE PRODUCTS LIMITED
205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD
UNAUDITED BALANCE SHEET AS AT 30th SEPTEMBER 2020

(Rs. in Lakhs)

	PARTICULARS	As at Sep 30, 2020	As at March 31, 2020
I	ASSETS:		
(1)	Non-current assets		
	(a) Property, Plant and Equipment	812.57	623.94
	(b) Capital work-in-progress	-	-
	(c) Goodwill	-	-
	(d) Other Intangible Assets	-	-
	(e) Biological Assets	-	-
	(f) Financial assets	-	-
	(i) Investments	-	-
	(ii) Other Financial Assets	-	-
	(g) Deferred tax assets (net)	33.59	33.59
	(h) Other non-current assets	-	-
	Total	846.16	657.53
(2)	Current assets		
	(a) Inventories	142.11	371.27
	(b) Financial assets	-	-
	(i) Investments	-	-
	(ii) Trade receivables	59.34	50.10
	(iii) Cash and cash equivalents	15.98	0.75
	(iv) Bank Balances other than (iii) above	-	-
	(v) Loans and advances	0.58	0.58
	(vi) Investments held for Sale	-	-
	(c) Other current assets	210.40	216.25
	Total	428.41	638.95
	TOTAL ASSETS	1,274.57	1,296.48
II	EQUITY AND LIABILITIES:		
	Equity		
	(a) Equity Share Capital	1,486.07	1,486.07
	(b) Other Equity	-	-
	Reserves and Surplus	-3,151.89	-3,077.93
	Total	-1,665.82	-1,591.86
	Liabilities		
(1)	Non Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	48.15	48.15
	(b) Deffered Tax Liability(Net)	69.17	69.17
	(c) Long Term Provisions	67.98	67.98
	(d) Other non current liabilities	-	-
	Total	185.30	185.30
(2)	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	1,651.09	1,710.75
	(ii) Trade Payables	746.36	592.08
	(iii) Other financial liabilities	-	-
	(b) Other current liabilities	357.64	400.21
	(c) Provisions	-	-
	(d) Current tax liabilities(Net)	-	-
	Total	2,755.09	2,703.04
	TOTAL EQUITY AND LIABILITIES	1,274.57	1,296.48

For SANGAM HEALTHCARE PRODUCTS LIMITED

A. Balagopal

A. Balagopal
Chairman and Managing Director
DIN:01712903



Place : Hyderabad
Date : 13/11/2020

SANGAM HEALTHCARE PRODUCTS LIMITED

205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD
CASH FLOW STATEMENT AS ON 30.09.2020

PARTICULARS	Rs. in Lakhs	
	30-09-2020	31-03-2020
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	-73.96	50.05
Adjustment for:		
Depreciation and Amortisation	62.77	125.55
Finance Cost recognised in Profit or Loss	0.12	29.45
Interest Income recognised in Profit or Loss	-	-1.78
Cash Flows from Operations before changes in assets and liabilities	-11.07	203.27
Movements in Working Capital:		
(Increase)/ Decrease in trade receivables	-9.24	-15.41
(Increase)/Decrease in other Current Assets	-	-
(Increase) / Decrease in Inventories	229.16	-93.93
(Increase) / Decrease in Loans and Advances & other current Assets	5.85	-55.82
Increase / (Decrease) in Trade and other payables	154.28	334.88
Increase / (Decrease) in Short term borrowings & provisions	-59.66	-1,725.17
Increase/(Decrease) in Other current liabilities	-42.57	-
Cash Generated From Operations	266.75	-1,352.18
Less: Taxes paid	-	-
Less: Exceptional Items	-	-291.54
Net Cash from operating activities(A)	266.75	-1,060.64
B. CASH FLOW FROM INVESTING ACTIVITIES		
Proceeds from disposal of Property,Plant and Equipment	-251.40	1,115.76
Investment in equity Shares	-	-
Interest Received	-	1.78
Net cash used in Investing activities (B)	-251.40	1,117.54
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	-
Repayment of Long Term Borrowings	-	-30.00
Interest paid	-0.12	-29.45
Increase / (Decrease) in Provisions	-	-1.82
Net cash Flow from Financing Activities (C)	-0.12	-61.27
D. Effect of exchange differences on translation of foreign currency cash and cash equivalents		
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	15.23	-4.37
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	0.75	5.12
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	15.98	0.75

For SANGAM HEALTHCARE PRODUCTS LIMITED

A. Balagopal

Chairman and Managing Director
DIN:01712903Place: Hyderabad
Date : 13/11/2020



M M REDDY & CO.,

Chartered Accountant

Phone : 040-65536097

Fax : 040-23478836

Mobile : 98482 71555

91770 20555

LIMITED REVIEW REPORT
UDIN: 20213077AAAAOM4840

To,
The Board of Directors,
SANGAM HEALTH CARE PRODUCTS LIMITED

We have reviewed the accompanying statement of Un-Audited Financial Results of **SANGAM HEALTH CARE PRODUCTS LIMITED** for the quarter ended **30th September, 2020** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M M Reddy & Co.,
Chartered Accountants


M Madhusudhana Reddy
Partner

Membership No. 213077

Place: Hyderabad

Date: 13/11/2020.

